Table 2 Multivariable survival analysis for immunofluorescence biomarkers. 95%CI 95% confidence interval, HR hazard ratio, PFS progression-free survival, OS overall survival. In the multivariable analysis, a P-value cut-off of ≤ 0.05 was considered statistically significant. Predictive model, a model exploring if the association between a biomarker and survival are significantly different depending on treatment arms: HR, 95%CI and P-values come from the interaction term. Clinical factors prognostic for PFS/OS were included in the model
Covariate name | Predictive model | |||||
|---|---|---|---|---|---|---|
PFS | OS | |||||
HR | 95%CI | P-value | HR | 95%CI | P-value | |
Clinical factors | ||||||
 FIGO stage (III/IV vs. I/II) | 2.384 | 1.181–4.815 | 0.015 | 1.994 | 0.893–4.454 | 0.092 |
 Debulking surgery outcome (≤ 1 cm vs. > 1 cm residual disease) | 0.243 | 0.147–0.399 | < 0.001 | 0.397 | 0.227–0.695 | 0.001 |
Immunofluorescence biomarker | ||||||
 c-MET/VEGFR-2 co-localisation (increase of expression) | 1.011 | 1.004–1.018 | 0.003 | 1.001 | 0.995–1.008 | 0.671 |
 Bevacizumab arm | – | – | ns | 1.116 | 0.995–1.008 | 0.669 |
Predictive significance | ||||||
 c-MET/VEGFR-2 co-localisation in bevacizumab arm (interaction) | – | – | ns | 1.034 | 1.010–1.059 | 0.006 |